ArticleEye (London, England)2025
Correlation between quality of vision and clinical and structural parameters in patients with Autosomal Dominant Optic Atrophy.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutosomal Dominant Optic Atrophy (ADOA) is a hereditary condition caused by mutations in the OPA1 gene, leading to progressive degeneration of the optic nerve fibres and subsequent visual decline. Despite advances in understanding its genetic and clinical aspects, the impact of ADOA on vision-related quality of life (VRQoL) remains poorly characterized. SUBJECTS/
methodsThis cross-sectional study aimed to evaluate VRQoL in 27 patients with molecularly confirmed ADOA using the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and its 10-item Neuro-Ophthalmic Supplement. Clinical and structural parameters, including visual acuity, colour vision, macular volume, and ganglion cell complex thickness, were assessed to explore their association with VRQoL scores.
resultsSignificant reduction in VRQoL, with mean composite scores of 74.1 (NEI-VFQ-25) and 69.9 (neuro-ophthalmic supplement) was observed. General vision, near activities, and distance activities were the most affected domains, while colour vision surprisingly scored higher than expected. Multivariate analysis revealed that best-corrected visual acuity (BCVA) to be independently associated with VFQ-25 composite (ß coefficient -66.46; p < 0.001), VFQ-25 neuroophthalmology (ß coefficient -57.13; p < 0.001) and 4 of the 12 subscales. Additionally, macular vessel density correlated with specific subscales such as dependency and colour vision.
conclusionsThese findings highlight the significant functional burden of ADOA on patients and underscore the importance of clinical parameters such as BCVA and peripapillary retinal nerve fibre layer in assessing the quality of life. The study suggests that preserving visual acuity should be a primary therapeutic target in ADOA management, as well as a key for monitoring and guiding future therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.